About bio path holdings inc - BPTH
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
BPTH At a Glance
Bio-Path Holdings, Inc.
4710 Bellaire Boulevard
Bellaire, Texas 77401
| Phone | 1-832-742-1357 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -9,894,000.00 | |
| Sector | Health Technology | Employees | 10 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BPTH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 43.446 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.143 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.049 |
BPTH Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -989,400.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
BPTH Liquidity
| Current Ratio | 1.146 |
| Quick Ratio | 1.146 |
| Cash Ratio | 0.356 |
BPTH Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -278.587 |
| Return on Equity | -3,325.714 |
| Return on Total Capital | -4,174.684 |
| Return on Invested Capital | -3,270.744 |
BPTH Capital Structure
| Total Debt to Total Equity | 53.896 |
| Total Debt to Total Capital | 35.021 |
| Total Debt to Total Assets | 2.138 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |